NCT00192348View on ClinicalTrials.gov

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

December 31, 2002

Conditions
Healthy
Interventions
BIOLOGICAL

CAIV-T

Trial Locations (1)

33014

University of Tampere, Tampere

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192348 - A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants | Biotech Hunter | Biotech Hunter